Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02866825
Other study ID # IFX-1-P2.2
Secondary ID 2015-003036-12
Status Completed
Phase Phase 2
First received June 17, 2016
Last updated February 14, 2017
Start date May 2016
Est. completion date January 2017

Study information

Verified date February 2017
Source InflaRx GmbH
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The trial enrolls patients undergoing a complex cardiac surgery. The primary goal of the trial is to evaluate the pharmacodynamic dose response relationship of the monoclonal antibody IFX-1 in these patients. In addition, this trial further aims to characterize the safety and the pharmacokinetics of IFX-1 as well as to collect first data on its efficacy on clinical surrogate endpoints.


Recruitment information / eligibility

Status Completed
Enrollment 116
Est. completion date January 2017
Est. primary completion date December 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Male or female patients = 18 years old

2. Written informed consent

3. One of the following cardiac surgical procedures is planned with Cardiopulmonary bypass (CPB):

- Single valve surgery in combination with at least two coronary artery bypass grafts (CABGs)

- Multiple valve surgery with or without CABG

- Single or multiple valve surgery in combination with ascending aorta procedure with or without additional CABG

- Re-surgery of aortic valve, mitral valve, aortic arch or ascending aorta with or without CABG

4. Cardiac surgery is performed electively

Exclusion Criteria:

1. Weight > 130 kg

2. The following cardiac surgical procedures:

- Cardiac surgical procedure is planned as minimally invasive procedure (e.g., without thoracotomy or with lateral incision, minimal thoracotomy)

- Cardiac surgery with an expected CPB time less than 100 minutes

3. Other cardiac and vascular diseases and/or procedures:

- Prior cardiac surgery within the past 6 months

- History of heart transplantation or planned heart transplantation

- Requiring inotropic, vasopressor or mechanical circulatory support

- Requiring ventilatory support

4. Other disease or condition that is likely to interfere with the evaluation of the study drug:

- Active infective endocarditis

- Stroke or transient ischemic attack (TIA) within the last 6 months

- Concomitant disease with a life expectancy of less than 6 months

- Cardiopulmonary resuscitation within the last 4 weeks

- Patients requiring renal replacement therapy

5. Cerebrovascular disease requiring concomitant carotid endarterectomy

6. Active infection with or without a temperature greater than 38°C

7. Presence of systemic inflammatory response syndrome defined as occurrence of at least 2 out of the following 4 criteria:

- Fever > 38.0°C or hypothermia < 36.0°C

- Tachycardia > 90 beats/minute

- Tachypnea > 20 breaths/minute

- Leucocytosis > 12 x 109/l or leucopenia < 4 x 109/l or > 10% immature neutrophils (bands)

8. Positive test for human immunodeficiency virus (HIV), hepatitis B or C

9. One of the following abnormal laboratory results:

- Hemoglobin < 5 mmol/l (< 8.06 g/dl)

- Total bilirubin = 2 x upper normal limit (UNL)

- CRP > 3 x UNL

- ALAT > 3 x UNL

- ASAT > 3 x UNL

- White blood cell count < 2,500/mm³

- White blood cell count > 12,000/mm³

10. Prohibited concomitant medications:

- Immunomodulatory drugs within past 30 days (e.g., TNF-inhibitors)

- Immunosuppressive drugs within past 30 days (e.g., cyclosporine, tacrolimus)

- High dose corticosteroids (e.g., > 50 mg prednisone/day or equivalent) within past 14 days

- Any systemic anticancer treatment within the past 3 months

11. Planned corticosteroid pulse therapy to prevent SIRS

12. Patients with known hypersensitivity to any constituent of the investigational medicinal product (IMP)

13. General exclusion criteria:

- Pregnant (in women of childbearing potential an urine pregnancy test has to be performed) or breast-feeding women

- Women with childbearing potential (defined as within two years of their last menstruation) not willing to practice appropriate contraceptive measures (e.g., implanon, injections, oral contraceptives, intrauterine devices, partner with vasectomy, abstinence) while participating in the trial

- Participation in any interventional clinical trial within the last three months

- Prior randomization in this clinical trial (screen failures can be re-screened, if appropriate)

- Alcohol, drug, or medication abuse

- Employee at the study site, spouse/partner or relative of any study staff (e.g., investigator, sub-investigators, or study nurse) or relationship to the sponsor

- No commitment to full aggressive life support (e.g., DNR order)

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
IFX-1

Placebo


Locations

Country Name City State
Germany Study Site Aachen
Germany Study Site Dortmund
Germany Study Site Dresden
Germany Study Site Freiburg
Germany Study Site Heidelberg
Germany Study Site Jena
Germany Study Site Kiel
Germany Study Site Leipzig
Germany Study Site Trier
Germany Study Site Tuebingen

Sponsors (1)

Lead Sponsor Collaborator
InflaRx GmbH

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Peak level of IL-6 From prior study drug administration until 24h after start of cardiopulmonary bypass (CPB) (CPB)
Secondary Plasma concentration of IFX-1 at each timepoint measured Data will be collected at the following approximate time points: prior study drug administration; 30 min after start of infusion; up to 10 min after cessation of CPB; 3h, 12h, 24h, 48h, 96h, and 168h after start of CPB; Day 15
Secondary Maximum observed concentration (Cmax) of IFX-1 Data will be collected at the following approximate time points: prior study drug administration; 30 min after start of infusion; up to 10 min after cessation of CPB; 3h, 12h, 24h, 48h, 96h, and 168h after start of CPB; Day 15
Secondary Area under the curve (AUC) of plasma concentration of IFX-1 Data will be collected at the following approximate time points: prior study drug administration; 30 min after start of infusion; up to 10 min after cessation of CPB; 3h, 12h, 24h, 48h, 96h, and 168h after start of CPB; Day 15
Secondary Plasma concentration of free, detectable C5a at each timepoint measured Data will be collected at the following approximate time points: prior study drug administration, prior start of CPB, up to 10 min after cessation of CPB; 3h, 6h, 12h, 24h, 48h, 96h, and 168h after start of CPB; Day 15
Secondary Serum levels of CH50 at each timepoint measured Data will be collected at the following approximate time points: prior study drug administration, prior start of CPB, up to 10 min after cessation of CPB; 3h, 6h, 12h, 24h, 48h, 96h, and 168h after start of CPB; Day 15
Secondary Serum levels of IL-6 compared to baseline Data will be collected at the following approximate time points: prior study drug administration, up to 10 min after cessation of CPB; 3h, 6h, 12h, 24h, 48h, and 96h after start of CPB; Day 15
Secondary Serum levels of IL-8 compared to baseline Data will be collected at the following approximate time points: prior study drug administration, up to 10 min after cessation of CPB; 3h, 6h, 12h, 24h, 48h, and 96h after start of CPB; Day 15
Secondary Incidence of patients with Adverse Events (AEs) and Serious Adverse Events (SAEs) until Day 29 From screening visit until Day 29
Secondary Number of patients with detection of anti-drug-antibodies Up to Day 15
Secondary Number of patients that are successfully extubated 24h after end of surgery 24h after end of surgery
Secondary Number of patients with consecutive invasive ventilation for more than 48h after end of surgery 48h after end of surgery
Secondary Number of patients that are weaned of any vasopressor use 24h after end of surgery 24h after end of surgery
Secondary Number of patients with SIRS 24h, 48h and 96h after start of CPB 24h, 48h and 96h after start of CPB
See also
  Status Clinical Trial Phase
Completed NCT02902939 - Myeloid-Derived Supressor Cells in Cardiac Surgery Patients N/A
Completed NCT02518087 - Increased Adsorption Membranes During Cardiopulmonary Bypass N/A
Completed NCT02563652 - Can Biomarkers Aid in the Prediction of Postoperative Pain and Circulatory Instability After Major Abdominal Surgery?
Recruiting NCT01157299 - Hemodynamic Evaluation of Preload Responsiveness in Children by Using PiCCO N/A
Completed NCT01388725 - Comparison the Value of Several Biomarkers of Sepsis N/A
Unknown status NCT00254176 - Cysteine Supplementation in Critically Ill Neonates Phase 2/Phase 3
Not yet recruiting NCT03617796 - Prognostic Value of CD64 Marker for Patients in Intensive Care Unit
Completed NCT03876041 - Evaluation of Corticosteroid in Systemic Inflammatory Response Syndrome Phase 4
Recruiting NCT05608096 - European Registry for Hemadsorption in Sepsis With the Seraph Filter
Completed NCT03314831 - The Role of Myristic Acid in Serum for Early Diagnosis of Sepsis and Comparison With Selected Biomarkers of Sepsis
Completed NCT02568410 - Platelets as Regulators of Inflammation in Cardiac Surgery
Completed NCT01636232 - Vitamin D and Critically Ill Patients N/A
Completed NCT01020409 - INFLACOR - Clinical and Genetic Predictors of Inflammation Related Complications After Heart Surgery Phase 4
Completed NCT04624776 - Steroid Treatment After Resuscitated Out-of-Hospital Cardiac Arrest Phase 2
Recruiting NCT05172739 - Opioid Free Anaesthesia-Analgesia Strategy on Surgical Stress and Immunomodulation in Elective VATS-Lobectomy for NSCLC Phase 4
Recruiting NCT02957175 - Immunophenotyping of Patients With Postoperative SIRS
Completed NCT02320539 - MicroRNA Diagnostics in Subarachnoid Hemorrhage 2 N/A
Completed NCT01708759 - IL8 Monitoring and Its Correlation With 251-gene Polymorphism N/A
Terminated NCT00708799 - Efficacy of Macrolide Immunomodulation in Severe Sepsis. Phase 2
Recruiting NCT04580680 - Extracorporeal Blood Purification Therapy in Critically Ill Patients (GlobalARRT)